ChemicalBook > Product Catalog >API >Antineoplastic agents >Other antineoplastic Drugs >Dilpacimab

Dilpacimab

Dilpacimab Suppliers list
Company Name: BOC Sciences
Tel: 16314854226; +8616314854226
Email: inquiry@bocsci.com
Products Intro: Product Name:Dilpacimab
CAS:1791420-09-1
Purity:95% Remarks:Please reach out to us for more information about custom solutions.
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com
Products Intro: Product Name:Dilpacimab
CAS:1791420-09-1
Purity:95% Package:100ug;500ug;1mg
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Products Intro: Product Name:Dilpacimab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
Company Name: Beijing Jin Ming Biotechnology Co., Ltd.  
Tel: 010-60605840
Email: psaitong@jm-bio.com
Products Intro: Product Name:Dilpacimab
CAS:1791420-09-1
Purity:>=95% Package:1mg;5mg
Company Name: Biolab Reagents  
Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Products Intro: Product Name:Research Grade Dilpacimab (DHJ65304)
CAS:1791420-09-1
Purity:PAGE:>95% Package:100ug;1mg
Dilpacimab Basic information
Product Name:Dilpacimab
Synonyms:Dilpacimab;Research Grade Dilpacimab (DHJ65304);Research Grade Dilpacimab
CAS:1791420-09-1
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Dilpacimab Structure
Dilpacimab Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Dilpacimab Usage And Synthesis
UsesDilpacimab (ABT165) is a potent dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.. Dilpacimab can be used in research of cancer[1].
References[1] Gordon MS, et, al. Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2021 Oct;20(10):1988-1995. DOI:10.1158/1535-7163.MCT-20-0985
Dilpacimab Preparation Products And Raw materials
Tag:Dilpacimab(1791420-09-1) Related Product Information
Laprituximab Nacolomabtafenatox Galegenimab Olendalizumab Rimteravimab Duvortuxizumab Recaticimab Suciraslimab Sudubrilimab Lulizumab Pegol